



PAPER • OPEN ACCESS

Phase-contrast microtomography: are the tracers necessary for stem cell tracking in infarcted hearts?

To cite this article: Alessandra Giuliani *et al* 2018 *Biomed. Phys. Eng. Express* 4 055008

View the [article online](#) for updates and enhancements.

Related content

- [Nanoparticle-based monitoring of cell therapy](#)
Chenjie Xu, Luye Mu, Isaac Roes *et al.*
- [Overview of hydrogel-based strategies for application in cardiac tissue regeneration](#)
Xuetao Sun and Sara S Nunes
- [Minimum number of detectable ¹¹¹In-tropolone-labelled mesenchymal stem cells](#)
Yuan Jin, Huafu Kong, Rob Z Stodilka *et al.*



PAPER

OPEN ACCESS

RECEIVED

19 April 2018

REVISED

13 July 2018

ACCEPTED FOR PUBLICATION

24 July 2018

PUBLISHED

2 August 2018

Original content from this work may be used under the terms of the [Creative Commons Attribution 3.0 licence](#).

Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.



Phase-contrast microtomography: are the tracers necessary for stem cell tracking in infarcted hearts?

Alessandra Giuliani¹ , Mara Mencarelli¹, Caterina Frati², Monia Savi³ , Costanza Lagrasta², Giulio Pompilio⁴, Alessandra Rossini⁵ and Federico Quaini⁶

¹ Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy

² Department of Medicine and Surgery, University of Parma, Parma, Italy

³ Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy

⁴ Vascular Biology and Regenerative Medicine Unit, Centro Cardiologico Monzino-IRCCS, Milan, Italy

⁵ Institute for Biomedicine, Eurac Research, Bolzano, Italy—Affiliated Institute of the University of Lübeck, Lübeck, Germany

⁶ Hematology and Bone Marrow Transplantation, University Hospital of Parma, Parma, Italy

E-mail: a.giuliani@univpm.it

Keywords: myocardium engineering, cardiac progenitor cells, phase-contrast microtomography, cell tracking, contrast agent, synchrotron radiation

Abstract

Recent literature has identified innovative approaches of cellular therapy to generate new myocardium involving transcortary and intramyocardial injection of cardiac progenitor cells (CPCs). One of the limiting factors in the overall interpretation of these preclinical results is the lack of reliable methods for 3D imaging and quantification of the injected cells and for the assessment of their fate within the myocardium. Here, for the first time to the authors' knowledge, we support by demonstrative experiments the hypothesis that phase-contrast microtomography (PhC-microCT) could offer an efficient 3D imaging approach to track the injected cells within the myocardium, without the need of any cell tracer. This deduction has been validated by several observations: (i) a strong phase-contrast signal was observed in infarcted hearts injected with unlabeled cells; (ii) the PhC-microCT 3D reconstructions of hearts injected with only vehicle saline solution and rhodamine particles, i.e. without CPCs, did not show any contrast; (iii) in the 3D PhC-microCT reconstructions of non infarcted hearts, injected with unlabeled CPCs, the contrast signal of the cells was present but differently distributed; and (iv) the contrast signal of injected cells diminished over time apparently following the same timing of cell engraftment and differentiation, as confirmed in literature by histology and fluorescence analysis. The chance to avoid cell tracers is of paramount interest in determining the fate of transplanted stem cells because the quantification of the signal will not be any more dependent on injected dose, concentration of the tracer, cell proliferation and tracer uptake kinetics.

1. Introduction

Cardiovascular diseases, in particular myocardial infarction (MI), are the leading causes of death in western world. Heart failure (HF), which is very often a direct consequence of MI (Roger 2013), represents nowadays a major health problem (Mozaffarian *et al* 2015, Benjamin *et al* 2017).

Promising innovative approaches, reported in recent literature, are based on cellular therapy aiming to generate new myocardium by transcortary and intramyocardial injection of cells.

Different cells have been employed, mainly of bone marrow (Strauer and Steinhoff 2011) and skeletal muscles (Menasché 2011) origin.

Unfortunately, systematic reviews of clinical trials on a large sample described contradictory results, sometimes reporting moderate or even no clinical benefits. Thus, the scientific community is in agreement with the contention that these results require further preclinical research.

In the last 10 years, increasing attention has also been paid to resident cardiac progenitor cells (CPCs), as alternative cell sources for the therapy of ischemic cardiomyopathies and HF. The approach is based on the rationale that the heart contains progenitor cells that, being programmed to generate myocardium, are better equipped to reconstruct the tissue lost with MI (Chamuleau *et al* 2009, Frati *et al* 2011, Leri *et al* 2011, Li *et al* 2012, Nadal-Ginard *et al* 2014, Savi *et al* 2016).

A special class of stem cells resident in the heart are cardiac mesenchymal stem cells (MSCs) (Leite *et al* 2015), which have been referred to in the literature as cardiac mesenchymal stem-like cells (Ryzhov *et al* 2014) and cardiac mesenchymal-like stromal cells (Rossini *et al* 2011, Vecellio *et al* 2012). These MSCs were recently identified in the cardiac stroma (Chong *et al* 2011).

However, regardless of the cell origin, a critical limiting factor that hampers a reliable interpretation of the retrieved results is the lack of efficient methods for the 3D imaging and quantification of the cells injected in the heart and for the detection of their fate within the myocardium.

Immunohistochemical approaches have the strength of being widely available, allowing information to be gained about cell viability, location, and fate as well as quantitative results, but measurements are subjected to variability and sampling errors, because a limited number of optical fields per section is typically examined (Terrovitis *et al* 2010). Moreover, quantitative data are affected by artifacts due to labeling techniques (Laflamme and Murry 2005, Reinecke *et al* 2008).

Bioluminescence imaging presents other limitations mainly linked to the low spatial resolution and the chance to obtain only surface images (Terrovitis *et al* 2010).

Labeling of stem cells with radiotracers has been experimented for studies using single photon emission computed tomography (SPECT) imaging and positron emission tomography (PET) for tracking cells (Hou *et al* 2005, Freyman *et al* 2006). However, SPECT showed some limitations in delivering precise quantitative data, mainly because of the errors derived from photon scattering, while PET, despite being very sensitive, is expensive, not widely available, and usually requires an on-site or nearby cyclotron for production of the necessary tracers (Terrovitis *et al* 2010). In addition, due to the short half-life of clinical grade radiolabeled isotopes, time restraint represents a limiting factor for long-term observations.

The direct radiolabeling limitations were bypassed by the use of reporter genes (Acton and Zhou 2005, Beeres *et al* 2007, Serganova *et al* 2007), but quantification of the signal was found to be not as precise as with PET, because the uptake depends on several factors: number of labeled cells, injected dose, arterial concentration of the tracer, regional blood flow, and tracer uptake kinetics (Su *et al* 2004). Moreover, with reporter gene approaches the tracers have to be injected systemically and in large amount to reach an appreciable detection, with a consequent increase in circulating radioactivity that decreases, in turn, the signal-to-noise ratio.

Cell labeling with iron particles for visualization by magnetic resonance imaging (MRI) is another

possibility and one of the most frequently applied methods for cell tracking. However, there are important pitfalls also associated to this technique, because iron nanoparticles released by dead cells are taken up by macrophages, persisting in the myocardium for up to 5 weeks and generating signals that could be misinterpreted as survived cells (Terrovitis *et al* 2010).

Recently, Giuliani *et al* (2011) showed that x-ray computed microtomography (microCT) offers the unique possibility of detecting in *ex vivo* conditions, with high definition and resolution, the 3D spatial distribution of rat cardiac progenitor cells (CPCs), previously labelled with iron oxide nanoparticles, inside infarcted rat heart one week after injection. No x-ray absorption contrast was found within a control rat heart, 1 week after injection of saline solution and rhodamine particles, suggesting that the microCT is able to specifically recognize the migrating labelled cells (Giuliani 2012).

However, there are still unresolved issues related to suitable assessments of myocardial regeneration by the available imaging methodologies. For instance, the inability to detect proliferation of the injected cells could result in an underestimation of cell engraftment due to hyper-dilution, possibly below the detection limit, or unequal distribution of the tracer on dividing cells. Furthermore, the use of nanoparticle tracers was proved to activate macrophages taking up tracers released by dying cells, as shown in by Gianella *et al* (2010) in case of Feridex-loaded endothelial progenitors into ischemic tissues.

Zehbe *et al* (2010) reported for the first time an unexpected evidence, revealing the microCT efficiency in tracking unlabeled stem cells once injected into a tissue or a substrate acting as scaffold. They proposed a rather simple methodology to control neuronal cell growth by applying an electrical potential. Synchrotron Radiation-based (SR) microCT was used to confirm in 3D the efficacy of the method. However, while the authors expected to observe just strongly absorbing deposited gold structures and weakly absorbing polymer substrates, interestingly, the unlabeled cells were well imaged and in good accordance with the fluorescence microscopic images acquired previously.

Furthermore, Albertini *et al* (2009) reported the first experience of SR-microCT study, exploiting the phase-contrast to visualize in 3D the extracellular matrix organization after *in vitro* seeding of bone marrow-derived human and murine mesenchymal stem cells induced to myogenic differentiation, labelled with iron oxide nanoparticles, and seeded onto polyglycolic acid-poly(lactic acid) scaffolds (PGA-PLLA).

Indeed, conventional microCT relies on attenuation of the x-ray beam intensity when passing through

the sample, while in PhC-microCT the beam phase shift caused by the sample is not measured directly, but is transformed into intensity variations (Snigirev and Snigireva 1995, Bravin *et al* 2013). This phase shift in non-mineralized biological tissues can be up to three orders of magnitude larger than attenuation (Momose *et al* 1996, Lewis *et al* 2003), explaining the highly increased contrast that has been observed with PhC-microCT, investigating different tissues and organs (Giuliani *et al* 2017).

Giuliani *et al* (2014) used the phase-contrast imaging to study *in vitro* cultures of different human progenitor cells, i.e. endothelial colony-forming cells from healthy controls and patients with Kaposi sarcoma and human CD133+ muscle-derived stem cells seeded onto PGA-PLLA. The method, despite the cells had not been labelled with any tracer, enabled to detect with high spatial resolution the 3D organization of cells on the bioscaffold and evaluation of the way and rate at which cells modified the construct at different time points from seeding.

Moreover, Fratini *et al* (2015) demonstrated that high-resolution x-ray phase contrast tomography is able to simultaneously visualize, in 3D and in *ex vivo* conditions, the micro-capillary network and the micrometric nerve fibers, the axon bundles and the neuron soma of the mouse's spinal cord. More recently, Bukreeva *et al* (2017) performed an innovative spatial statistical analysis on the motor neurons to obtain quantitative information on their 3D arrangement in healthy-mice spinal cord and in a mouse model of multiple sclerosis. It is interesting to note that all these results were obtained with scales ranging from millimeters to hundreds of nanometers, without contrast agents and in non-destructive ways.

Thus, in this demonstrative investigation, basing on the studies previously reported, we discuss the rightness of the x-ray phase-contrast microtomography (PhC-microCT) approach to track unlabeled cells within the myocardium.

2. Materials and methods

Ten Wistar male rats (12/14 weeks old, 350/400 g) were involved in the study and were kept, fed and sacrificed following a procedure approved by Veterinary Animal Care and Use Committee of the University of Parma, in compliance with National Ethical Guidelines (Italian Ministry of Health; DL.vo. 116, 1992) and the Guide for Care and Use of Laboratory Animals (NIH publication n. 85-23, revised 1996). In order to induce myocardial infarction in the left ventricle, a thoracotomy in correspondence of third intercostal space and a ligature around the left descending coronary vessel were performed, as reported by Giuliani *et al* (2011). Three weeks after surgical intervention, the rat chest was opened again to directly inject 5×10^5 stem cells in the ligature site.

Five animals received injection of rat cardiac progenitor cells (rCPCs), the remaining five ones the same quantity of human cardiac stromal cells (hCStCs). The rCPCs were obtained from atrial auricle of Wistar rats, as reported by Giuliani *et al* (2011), while the hCStCs were collected from the same site of donor patients undergoing cardiac surgery under the approval of Local Ethics Committee and after informed consent obtained in accordance with the Declaration of Helsinki (Rossini *et al* 2011).

Four cell manipulation protocols were adopted for both rCPCs and hCStCs: in the first one the cells were labelled with iron oxide nanoparticles (Feridex), in the second cells were cultured with Insulin-Transferrin-Sodium Selenite (ITS) growth factor, while the last two situations consisted in total absence or combined use of Feridex and ITS.

Times-to-sacrifice were chosen 24–48 h, 12–13 days, 21 days and 30 days after cell injection.

2.1. X-ray phase-contrast microtomography (PhC-microCT)


MicroCT experiments were carried out at the beamline ID19 of the European Synchrotron Radiation Facility (ESRF) of Grenoble, France. The photon energy was set to 15 keV with a multilayer monochromator (Weitkamp *et al* 2010). 2000 projections of 2048×2048 pixels each (pixel size of $5 \mu\text{m}$) were acquired at equidistant angular positions over 360° . The exposure time for each projection was 0.3 s. The scans were performed on the intact rat hearts at a z distance between specimen and detector of 25 mm. The phase-contrast can be recovered from a single sample-detector distance under the assumption of a single material specimen and monochromatic illumination. Thus, phase retrieval was performed using the software ANKPhase (Weitkamp *et al* 2011) which is based upon an algorithm presented by Paganin *et al* (2002), assuming that

$$z \ll \frac{d^2}{\lambda}$$

where d is the size of the smallest objects identifiable in the specimen and λ is the x-ray wavelength. In this experiment $d \sim 10 \mu\text{m}$ and $\lambda = 0.826 \text{ \AA}$: therefore, the z distance was chosen according to the rationale that it should have been much smaller than 1200 mm.

3. Results

Figure 1(A) shows a schematic representation of the mechanisms through which CPCs are imaged by propagation-based PhC-microCT. The injected CPCs, at an initial stage, are not integrated with the hosting myocardium, as shown in figure 1 (panel A-I). Pronounced edge enhancement can be seen by imaging the injected CPC at a sample-detector distance included in the Fresnel region (Mayo *et al* 2002,



Gureyev 2003) (figure 1, panel A-II). Thus, as shown in the 3D reconstruction of a rat heart subvolume—corresponding to the inner wall of the infarcted left-ventricle (figure 1, panel A-III)—the unlabeled CPCs (indicated by the red arrows) are clearly visible inside the damaged ventricle.

Indeed, the axial sections, reconstructed without the application of the Paganin filter, showed the presence of structures, *white spots*, mainly concentrated in

the infarcted area of the ventricle (figure 1, panel B). This observation is not justified by any evident scientific motivation, since the cells had not been labeled with tracers before injection.

Moreover, this contrast cannot be explained arguing that the sample preparation procedure was affected by contaminants with high atomic number Z . Indeed, the non-infarcted heart of a control rat, injected with only vehicle saline solution containing

rhodamine particles (but not cells) and prepared and sacrificed with the same procedure, did not show any contrasted signal in the whole heart, as shown and demonstrated by Giuliani (2012).

This unexpected signal was found to be due to phase contrast, using a comparative test performed on a laboratory-based microCT device. An infarcted rat heart injected with 5×10^5 rCPCs, previously cultivated in the absence of the Feridex tracer, was studied by means of a Skyscan 1174 (Bruker, Kontich, Belgium), with a voltage of 50 kV, no filter and pixel dimensions of $9.5 \mu\text{m}$ (figure 1, panel C-I). In fact, in conventional radiological imaging, image formation is based on differences in the absorption of sample details, i.e. dense structures absorb more than soft tissues. The conventional microCT is based on the mapping of the linear attenuation coefficient of x-rays that cross the studied sample, where the attenuation depends on the density of the object. Thus, if the white spot signal had been due to absorption, these spots would have been illuminated even using conventional microCT. Instead, as shown in figure 1, panel C-II, the strong contrast is no longer present in the 3D reconstruction, when the myocardium has been virtually rendered translucent to visualize the internal structures. This observation confirmed that the white spots were due to phase contrast.

We have also shown that the signal is related to the presence of the unlabeled injected cells with multiple evidences.

A photo of an infarcted rat heart and the PhC-microCT 3D reconstructions of three examined rat hearts were shown in figures 2(A) and (B)–(D), respectively.

First, it was found that the contrast signal was present (figure 2(B)) also in a non-infarcted rat heart, injected with the same CPCs amount of the infarcted rats. In this case, the signal was more homogeneously distributed within the heart, likely because the injected cells were not attracted by any injury.

Secondly, as investigated and described in Giuliani *et al* (2011), to further document cell homing, rCPCs were loaded, before their injection, with 585 Quantum Dots (QDot). In tissue preparations, rCPCs were found in all regions of the heart, although QDot-fluorescence signals were accumulated and uniformly distributed in the infarcted and peri-infarcted regions. Moreover, evidences of rCPC homing and engraftment have been also supported by Savi *et al* (2016) and a further example is reported in figure 3.

Third, the demonstrative study on the 10 infarcted rat hearts injected with CPCs seems to confirm, also on a quantitative level, that the observed phase-contrast signal derives from the injected cells. Indeed, we introduced three criteria of inclusion for the groups-of-study identification: (1) cell nature (rat CPCs or human CStCs), (2) treatment protocol, and (3) time from cell injection to rat sacrifice. The first assessment

was performed fixing the former two variables, in order to study the effect of time from cell injection. Quantitative results are shown in figure 4.

In the early phase, between 24–48 h and 12–13 days, there was a clear increase of the aggregate cell volume in hearts injected with rCPCs, previously cultured with ITS and independently to the presence of the Feridex contrast agent, possibly indicating a proliferation of cardiac progenitor cells and/or an activation of the endogenous stem cells. Interestingly, the cell volume detected in the infarcted area decreased with time, when cells were previously labeled with Feridex.

In case of hearts injected with hCPCs, previously cultured with ITS and Feridex, the aggregate cell volume was confirmed to increase during the first 21 days, with an important reduction from 21 to 30 days from the cell injection. Coherently with the previous case, the cell volume detected in the infarcted area decreased with time, when cells were previously labeled with Feridex.

The aggregate cell volume was confirmed to decrease, from 21 to 30 days after the cell injection, also in the case of rat hearts injected with hCStCs, previously cultured with ITS and without Feridex. The 3D reconstructions are shown in figure 2 at 21 days (panel C) and 30 days (panel D) from cell injection. Notably, the overall cellular volume in this experimental condition reached, at 21 days from hCStCs injection, the amount of $5.3 \times 10^9 \mu\text{m}^3$, more than 3-fold greater than in hearts injected with hCStCs, cultured with ITS and Feridex, at the same time-point (figure 4).


4. Discussion

The propagation-based PhC-microCT (Snigirev and Snigireva 1995, Wilkins *et al* 1996, Cloetens *et al* 1999), by placing the detector and the sample at a moderate distance, produces contrast by Fresnel diffraction and is usually preferred to other phase-contrast methods when highly-resolved images are desired, because no optical components are necessary if a coherent x-ray source, like synchrotron light, is used.

In the present study, this method enabled us to track unlabeled CPCs injected in infarcted rat hearts at different time points, with fundamental information about their kinetics, confirmed in literature by histology and fluorescence analysis.

Our observations strongly support the following hypothesis:

1. The phase contrast is able to discriminate the myocardium from the injected cells due to changes in electronic density and/or misalignments in the form and lack of integration (engraftment) between the regular myocardial pattern and the injected cells;



2. The aggregate cell volume increases for the first 21 days from cell injection, possibly indicating a proliferation of the injected cells and/or an activation of the endogenous stem cells;
3. The aggregate cell volume decreases from 21 to 30 days from cell injection, possibly indicating the completion of differentiation and cell integration in the myocardium. This observation is in line with a previous report (Rossini *et al* 2011), showing that after 21 days from injection in the same rat model of chronic MI, a fraction of the injected CStCs exhibited evident sarcomere striation and volume compatible with that of adult cardiac myocytes;
4. Feridex nanoparticles seem to interfere with the spontaneous regeneration process activated by CPCs, possibly because of an overlapping action of macrophages, as previously observed by Gianella *et al* (2010);




Figure 3. Myocardial regeneration in the peri-infarcted area of a rat heart injected with Green Fluorescence Protein (GFPpos) rat CPCs. Green fluorescence corresponds to GFP, red fluorescence to α -sarcomeric actin (α -SA). Arrows indicate cardiomyocytes generated by GFPpos CPCs, showing by yellowish fluorescence the co-expression of GFP (green) and α -SA (red). Resident spared cardiomyocytes are labelled by α -SA only. The blue fluorescence corresponds to DAPI staining of nuclei. Scale bar = 50 μ m.

5. ITS seems to enhance tissue regeneration, possibly favoring cell engraftment, as shown by Terrovitis *et al* (2010), and CPC proliferation.

Giuliani *et al* (2011) demonstrated by two alternative imaging techniques, based on different tracers, the ability of microCT to trace cells from the injection area to the infarcted area: the first was based on labeling the injected cells with QDots nanocrystals, the second was dependent on a genetic marker to visualize the progeny of the injected cells in the infarcted heart.

However, all these tracers influence a reliable quantitative analysis for the different reasons previously described and there are not, to date, alternative diagnostic techniques to PhC-microCT that do not require the use of tracers.

Thus, the full comprehension of the origin of the contrast in the injected cells is not trivial. In principle, two scenarios can originate edge-enhancement in PhC-microCT: the lacking of integration (engraftment) of the injected cells in the regular myocardial pattern and/or mismatches in electronic density between the injected cells and the surrounding tissues. While the first condition is certainly present, because we investigated the hearts at early stages after the CPCs injection, i.e. before the necessary times for a complete grafting, we strongly suspect that the contrast is mainly linked to mismatches in electronic density due to the presence of matrix metalloproteinases (MMPs) all around the injected stem cells. MMPs, also called matrixins, act in the extracellular environment of cells, degrading both matrix and non-matrix proteins. They were proved to have a fundamental role in morphogenesis, wound healing, tissue repair and remodeling after an injury, as in the case of a myocardial infarction (Nagase *et al* 2006).

Shen *et al* (2016) elucidated the effects of MMP inhibition on the therapeutic benefits of intramyocardial injection of platelet fibrin gel spiked with cardiac stem cells in a rat model of acute MI. In a syngeneic rat model of myocardial infarction, MMP inhibition blunted the recruitment of endogenous cardiovascular cells into the injected biomaterials, therefore hindering de novo angiogenesis and cardiomyogenesis.


However, these interactions are not fully understood and warrant further investigation, not only to better understand the origin of the edge-enhancement contrast but also and above all for their application as therapeutic tools to treat different diseases, including MI.

In this direction, our observations have two limitations: the small number of samples, which hinders any statistical speculation, and the absence of systematic assessments of the infarcted area, necessary to make a completely reliable quantitative comparison between the samples.

However, the calculated cell volumes were significantly and systematically different, depending on the different experimental parameters (time from the injection of the cells to the sacrifice, presence/absence of contrast medium and type of medium). Thus, this study deserves an accurate experimental verification using appropriate statistical approaches.

5. Conclusions

We have shown that PhC-microCT is an imaging method of fundamental interest in determining, in *ex-vivo* conditions, the fate of transplanted stem cells. The chance to avoid cell tracers, will substantially improve the reliability of quantitative analysis, being



the signal not anymore dependent on injected dose, concentration of the tracer, cell proliferation and tracer uptake kinetics. Hearts have been studied in *ex-vivo* conditions for several reasons: to increase the resolution for the injected cells detecting, to avoid movement problems due to the heartbeat and, last but not least, to avoid problems due to the x-ray dose.

However, the exploitation of phase contrast tomography promises to offer the interesting possibility of creating a fundamental change in medical radiological imaging. A considerable number of experiments have already demonstrated a significantly improved contrast compared to conventional methods, revealing soft tissue discrimination at micro and nanometric resolutions, at somewhat lower doses than those required by conventional radiological imaging.

Although the use of synchrotrons has revealed the possibilities offered by PhC-microCT, unfortunately the application of these ideas in a clinical context

requires that the tomographic technology will be further improved in several areas, including x-ray sources, optics and detectors (Lewis 2004). Indeed, longitudinal studies at synchrotrons are currently hindered by the limited synchrotron accessibility (due to competitive application procedures for beamtime). In contrast, benchtop microCT devices usually present small-scale experimental configurations, i.e. comparable in size to the diagnostic CT scanners: therefore, they could be installed directly on the site where the research is performed, resulting in an improved accessibility.

Several different x-ray phase contrast settings have been developed over the last years to be implemented in laboratory microCT systems. Most of them (Propagation-based imaging, Grating interferometry, Edge illumination and Zernike phase contrast) were firstly realized for synchrotron radiation-based tomography and later modified for use with standard x-ray tubes.

They are mainly used to image soft (non-mineralized) tissues, often resolving the internal micro-morphology of stained and unstained tissues as well as the 3D distribution of cells within engineered constructs (Shearer *et al* 2016). Moreover, benchtop x-ray nanotomography was shown to efficiently resolve several native tissues and organs, allowing to also perform histological and immunohistochemical analysis after the microCT, showing that the exposure to x-rays and some x-ray contrast agents seem not affect the sub-micron morphology (Walton *et al* 2015).

However, the implementation of x-ray phase contrast tomography outside synchrotrons, to date, still presents several problems: x-rays offer limited spatial and temporal coherence, source drifts or environmental vibrations could affect the scanning and, main problem in the experimentation described in the present study, it is not possible to achieve sufficiently fast scan times because of the relatively low flux emitted by x-ray tubes. Indeed, laboratory-based phase contrast tomography still fails in achieving fast acquisitions, dramatically affecting the *in vivo* imaging of the heart due to cardiac motion.

The recent literature suggests that the previously mentioned restrictions of laboratory-based phase contrast tomography could be overcome in due course. Indeed, as discussed by Marenzana *et al* (2014), additional improvements may lead to a new generation of coded-aperture x-ray phase-contrast microCT scanners, suitable for *in vivo* longitudinal pre-clinical imaging of soft tissue and with resolutions significantly higher than the current magnetic resonance imaging.

Acknowledgments

The authors acknowledge the ESRF User Office for kindly providing beamtime, and Dr Elodie Boller for technical support during the experiments. This work arises from a collaboration between BIONECA CA16122 partners (AG and FQ).

ORCID iDs

Alessandra Giuliani  <https://orcid.org/0000-0003-4177-7441>

Monia Savi  <https://orcid.org/0000-0002-7895-7756>

References

- Acton P D and Zhou R 2005 Imaging reporter genes for cell tracking with PET and SPECT *Q J Nucl Med Mol Imaging* **49** 349–60
- Albertini G *et al* 2009 Organization of extracellular matrix fibers within polyglycolic acid-poly(lactic acid) scaffolds analyzed using x-ray synchrotron-radiation phase-contrast micro computed tomography *Tissue Eng. Part C Methods* **15** 403–11
- Beeres S L, Bengel F M, Bartunek J, Atsma D E, Hill J M, Vanderheyden M, Penicka M, Schalij M J, Wijns W and Bax J J 2007 Role of imaging in cardiac stem cell therapy *J. Am. Coll. Cardiol.* **49** 1137–48
- Benjamin E J *et al* 2017 American heart association statistics committee, stroke statistics subcommittee. Heart disease and stroke statistics—2017 update: a report from the American heart association *Circulation* **135** e146–603
- Bravin A, Coan P and Suortti P 2013 X-ray phase-contrast imaging: from pre-clinical applications towards clinics *Phys. Med. Biol.* **58** R1–35
- Bukreeva I *et al* 2017 Quantitative 3D investigation of Neuronal network in mouse spinal cord model *Sci. Rep.* **7** 41054
- Chamuleau S A J, Vrijssen K R, Rokosh D G, Tang X L, Piek J J and Bolli R 2009 Cell therapy for ischaemic heart disease: focus on the role of resident cardiac stem cells *Neth Heart J.* **17** 199–207
- Chong J J H *et al* 2011 Adult cardiac-resident MSC-like stem cells with a proepicardial origin *Cell Stem Cell.* **9** 527–40
- Cloetens P, Ludwig W and Baruchel J 1999 Holotomography: quantitative phase tomography with micrometer resolution using hard synchrotron radiation x rays *Appl. Phys. Lett.* **75** 2912
- Fрати C *et al* 2011 Resident cardiac stem cells *Curr Pharm Des.* **17** 2074–99
- Fratini M *et al* 2015 Simultaneous submicrometric 3D imaging of the micro-vascular network and the neuronal system in a mouse spinal cord *Sci. Rep.* **5** 8514
- Freyman T, Polin G, Osman H, Crary J, Lu M, Cheng L, Palasis M and Wilensky R L 2006 A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction *Eur. Heart J.* **27** 1114–22
- Gianella A, Guerrini U, Tilenni M, Sironi L, Milano G, Nobili E, Vaga S, Capogrossi M C, Tremoli E and Pesce M 2010 Magnetic resonance imaging of human endothelial progenitors reveals opposite effects on vascular and muscle regeneration into ischaemic tissues *Cardiovasc Res.* **85** 503–13
- Giuliani A *et al* 2011 High-resolution x-ray microtomography for three-dimensional imaging of cardiac progenitor cell homing in infarcted rat hearts *J. Tissue Eng. Regen. Med.* **5** e168–78
- Giuliani A 2012 3D visualization of transplanted stem cells in infarcted rat hearts by high-resolution x-ray microtomography *IL NUOVO CIMENTO* **35** C 157–67
- Giuliani A *et al* 2014 Polyglycolic acid-poly(lactic acid) scaffold response to different progenitor cell *in vitro* cultures: a demonstrative and comparative x-ray synchrotron radiation phase-contrast microtomography study *Tissue Eng. Part C Methods* **20** 308–16
- Giuliani A, Mazzoni S, Mele L, Liccardo D, Tromba G and Langer M 2017 Synchrotron phase tomography: an emerging imaging method for microvessel detection in engineered bone of craniofacial districts *Front. Physiol.* **8** 769
- Gureyev T E 2003 Composite techniques for phase retrieval in the Fresnel region *Opt. Commun.* **1** 220 49–58
- Hou D, Youssef E A, Brinton T J, Zhang P, Rogers P, Price E T, Yeung A C, Johnstone B H, Yock P G and March K L 2005 Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials *Circulation* **112** I150–6
- Laflamme M A and Murry C E 2005 Regenerating the heart *Nat. Biotechnol.* **23** 845–56
- Leite C F, Almeida T R, Lopes C S, Dias and da Silva V J 2015 Multipotent stem cells of the heart—do they have therapeutic promise? *Front. Physiol.* **6** 123
- Leri A, Kajstura J and Anversa P 2011 Role of cardiac stem cells in cardiac pathophysiology: a paradigm shift in human myocardial biology *Circ. Res.* **109** 941–61
- Lewis R A *et al* 2003 X-ray refraction effects: application to the imaging of biological tissues *Brit. J. Radiol.* **76** 301–8
- Lewis R A 2004 Medical phase contrast x-ray imaging: current status and future prospects *Phys. Med. Biol.* **49** 3573
- Li T S *et al* 2012 Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiospherederived cells *J. Am. Coll. Cardiol.* **59** 942–53

- Marenzana M *et al* 2014 Synchrotron- and laboratory-based x-ray phase-contrast imaging for imaging mouse articular cartilage in the absence of radiopaque contrast agents *Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences* **372** 20130127
- Mayo S *et al* 2002 Phase-contrast x-ray projection microscopy for materials characterization *Mater. Forum* **26** 15–9
- Menasché P 2011 Cardiac cell therapy: lessons from clinical trials *J Mol Cell Cardiol.* **50** 258–65
- Momose A, Takeda T, Itai Y and Hirano K 1996 Phase-contrast x-ray computed tomography for observing biological soft tissues *Nat. Med.* **2** 473–5
- Mozaffarian D *et al* 2015 American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update: a report from the American Heart Association *Circulation* **131** e29–322 ; Corrigendum (2015) *Circulation* **131** e98; *Circulation* **131** e117; *Circulation* **131** e163; *Circulation* **131** e319
- Nadal-Ginard B, Ellison G M and Torella D 2014 The cardiac stem cell compartment is indispensable for myocardial cell homeostasis, repair and regeneration in the adult *Stem Cell Res.* **13** 615–30
- Nagase H, Visse R and Murphy G 2006 Structure and function of matrix metalloproteinases and TIMPs *Cardiovasc Res.* **15** 69 562–73
- Paganin D, Mayo S C, Gureyev T E, Miller P R and Wilkins S W 2002 Simultaneous phase and amplitude extraction from a single defocused image of a homogeneous object *J. Microsc.* **206** 33–40
- Reinecke H, Minami E, Zhu W Z and Laflamme M A 2008 Cardiogenic differentiation and transdifferentiation of progenitor cells *Circ. Res.* **103** 1058–71
- Roger V L 2013 Epidemiology of heart failure *Circ. Res.* **113** 646–59
- Rossini A *et al* 2011 Human cardiac and bone marrow stromal cells exhibit distinctive properties related to their origin *Cardiovasc Res.* **89** 650–60
- Ryzhov S, Sung B H, Zhang Q, Weaver A, Gumina R J, Biaggioni I and Feoktistov I 2014 Role of adenosine A2B receptor signaling in contribution of cardiac Mesenchymal stem-like cells to myocardial scar formation *Purinergic Signal.* **10** 477–86
- Savi M *et al* 2016 Antiarrhythmic effect of growth factor-supplemented cardiac progenitor cells in chronic infarcted heart *Am. J. Physiol. Heart. Circ. Physiol.* **310** H1622–48
- Serganova I, Ponomarev V and Blasberg R 2007 Human reporter genes: potential use in clinical studies *Nucl Med Biol.* **34** 791–807
- Shearer T, Bradley R S, Hidalgo-Bastida L A, Sherratt M J and Cartmell S H 2016 Three-dimensional visualisation of soft biological structures by x-ray computed micro-tomography *J Cell Sci* **129** 2483–92
- Shen D *et al* 2016 Effects of matrix metalloproteinases on the performance of platelet fibrin gel spiked with cardiac stem cells in heart repair *Stem Cells Transl. Med.* **5** 793–803
- Snigirev S and Snigireva I 1995 On the possibilities of x-ray phase contrast microimaging by coherent high-energy synchrotron radiation *Rev. Sci. Instrum.* **66** 5486–92
- Strauer B E and Steinhoff G 2011 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice *J. Am. Coll. Cardiol.* **58** 1095–104
- Su H, Forbes A, Gambhir S S and Braun J 2004 Quantitation of cell number by a positron emission tomography reporter gene strategy *Mol Imaging Biol.* **6** 139–48
- Terrovitis J V, Smith R R and Marbán E 2010 Assessment and optimization of cell engraftment after transplantation into the heart *Circ. Res.* **106** 479–94
- Vecellio M *et al* 2012 *In vitro* epigenetic reprogramming of human cardiac mesenchymal stromal cells into functionally competent cardiovascular precursors *PLoS ONE* **7** e51694
- Walton L A *et al* 2015 Morphological characterisation of unstained and intact tissue micro-architecture by x-ray computed micro- and nano-tomography *Sci. Rep.* **5** 10074
- Weitkamp T *et al* 2010 Status and evolution of the ESRF beamline ID19 *AIP Conf. Proc.* **1221** 33–8
- Weitkamp T, Haas D, Wegrzynek D and Rack A 2011 ANKAphase: software for single-distance phase retrieval from inline x-ray phase-contrast radiographs *J. Synchrotron Rad.* **18** 617–29
- Wilkins S W, Gureyev T E, Gao D, Pogany A and Stevenson A W 1996 Phase-contrast imaging using polychromatic hard x-rays *Nature* **384** 335–8
- Zehbe R, Haibel A, Schmidt F, Riesemeier H, Kirkpatrick C J, Schubert H and Brochhausen C 2010 High resolution x-ray tomography—3D imaging for tissue engineering applications *Tissue Eng.* ed D Eberli (Rijeka, Croatia: InTech) pp 337–58